Immunogenic and thrombolytic properties of PEGylated SakSTAR variants in rabbits
| Neutralizing Activity (μg/mL) . | Clot Lysis (%) . | |||
|---|---|---|---|---|
| Compound . | Baseline (Week 0) . | (Week 6) . | (Week 0) . | Week 6 . |
| SakSTAR | 0.3 (0.1-0.7) | 20 (5-53) | 53 (44-62) | 3 (2-6) |
| SakSTAR(K109C-SP5) | 0.6 (0-1) | 22 (2-61) | 60 (30-82) | 4 (3-33) |
| SakSTAR(K135C-SP5) | 2 (0-7) | 9 (0-27) | 36 (25-43) | 5 (3-47) |
| SakSTAR(K96C-SP5, K135C-SP5) | 0 (0-12) | 16 (0-125) | 40 (24-56) | 4 (2-30) |
| Neutralizing Activity (μg/mL) . | Clot Lysis (%) . | |||
|---|---|---|---|---|
| Compound . | Baseline (Week 0) . | (Week 6) . | (Week 0) . | Week 6 . |
| SakSTAR | 0.3 (0.1-0.7) | 20 (5-53) | 53 (44-62) | 3 (2-6) |
| SakSTAR(K109C-SP5) | 0.6 (0-1) | 22 (2-61) | 60 (30-82) | 4 (3-33) |
| SakSTAR(K135C-SP5) | 2 (0-7) | 9 (0-27) | 36 (25-43) | 5 (3-47) |
| SakSTAR(K96C-SP5, K135C-SP5) | 0 (0-12) | 16 (0-125) | 40 (24-56) | 4 (2-30) |
Data represent median and range of 8 experiments.